MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by StockNews.com

MiMedx Group (NASDAQ:MDXG) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Friday.

MDXG has been the topic of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a report on Thursday, August 1st. Craig Hallum dropped their target price on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.00.

MiMedx Group Stock Down 0.8 %

Shares of NASDAQ:MDXG opened at $7.44 on Friday. The business’s 50 day simple moving average is $6.10 and its two-hundred day simple moving average is $6.69. The firm has a market cap of $1.09 billion, a P/E ratio of 13.53 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group has a 52-week low of $5.47 and a 52-week high of $9.27.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Paradigm Capital Management Inc. NY increased its position in shares of MiMedx Group by 6.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after acquiring an additional 258,700 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after acquiring an additional 413,443 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after acquiring an additional 770,744 shares during the last quarter. Royce & Associates LP increased its position in shares of MiMedx Group by 5.3% during the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after acquiring an additional 48,539 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of MiMedx Group by 339.9% during the second quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock valued at $6,164,000 after acquiring an additional 687,267 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.